🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 18 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
24/09/2013 47,80 48,78 46,63 47,61 -0,75% 4,50% 2.693.700
23/09/2013 43,41 49,19 43,40 47,97 +10,79% 13,34% 6.580.100
20/09/2013 37,79 46,16 36,07 43,30 +18,02% 26,70% 15.737.700
19/09/2013 36,99 37,42 36,17 36,69 -0,46% 3,38% 1.514.200
18/09/2013 37,70 37,70 36,44 36,86 -0,43% 3,34% 918.000
17/09/2013 36,25 37,15 35,92 37,02 +1,82% 3,39% 796.400
16/09/2013 37,60 38,54 36,08 36,36 -2,28% 6,54% 1.593.800
13/09/2013 36,78 38,16 36,70 37,21 +1,33% 3,97% 1.788.700
12/09/2013 36,16 37,30 35,31 36,72 +1,18% 5,50% 917.800
11/09/2013 36,80 37,05 36,16 36,29 -1,87% 2,42% 580.400
10/09/2013 37,17 37,30 36,40 36,98 +0,00% 2,42% 620.100
09/09/2013 36,68 37,36 36,30 36,98 +0,71% 2,89% 819.700
06/09/2013 36,87 37,48 36,16 36,72 +0,82% 3,58% 1.001.100
05/09/2013 36,31 36,73 35,90 36,42 +0,30% 2,29% 583.500
04/09/2013 35,58 36,50 35,32 36,31 +2,28% 3,32% 825.600
03/09/2013 34,49 35,64 34,45 35,50 +4,01% 3,45% 957.400
30/08/2013 34,50 34,75 33,53 34,13 -0,58% 3,54% 924.300
29/08/2013 34,66 35,37 33,86 34,33 -0,89% 4,36% 1.014.100
28/08/2013 33,99 34,94 33,99 34,64 +1,97% 2,79% 770.200
27/08/2013 34,47 35,49 33,81 33,97 -3,08% 4,87% 1.442.300
26/08/2013 33,80 35,33 33,80 35,05 +4,16% 4,53% 1.389.400
23/08/2013 32,49 33,72 32,47 33,65 +3,89% 3,85% 1.061.500
22/08/2013 32,55 33,15 32,15 32,39 -0,18% 3,07% 378.000
21/08/2013 32,30 32,94 31,80 32,45 +0,46% 3,53% 808.800
20/08/2013 31,10 33,04 30,91 32,30 +4,50% 6,85% 2.112.100
19/08/2013 32,89 33,17 29,71 30,91 -6,56% 10,52% 4.452.900
16/08/2013 33,60 34,71 32,45 33,08 +3,25% 6,73% 3.065.700
15/08/2013 32,27 33,05 31,87 32,04 -1,81% 3,66% 1.145.900
14/08/2013 31,44 33,07 31,08 32,63 +3,46% 6,33% 1.980.300
13/08/2013 32,90 32,96 31,25 31,54 -3,19% 5,20% 2.529.700